Armour Thyroid Microdosing Protocols: What the Evidence Actually Shows

What "Microdosing" Means in the Context of NDT

The term microdosing has no formal pharmacological definition in thyroid medicine. In practice, clinicians use it to describe starting Armour Thyroid at doses well below the expected full replacement amount, typically 15-30 mg daily, before titrating upward. This approach is borrowed from general endocrine prescribing logic: start low, go slow, and reassess on a defined schedule.

Full replacement for most adults with primary hypothyroidism lands between 1 and 2 grains (60-120 mg) daily, depending on lean body mass and residual thyroid function [1]. A 15 mg starting dose therefore represents roughly one-quarter of the lower bound of replacement, which fits a functional definition of a microdose.

Why Clinicians Start Below Replacement

Several physiological reasons support a gradual approach, particularly in patients who have been hypothyroid for months or years.

Cardiac tissue adapts to low thyroid output. A rapid surge in circulating T3, which peaks within 2-4 hours of an NDT dose, can precipitate palpitations or atrial ectopy in sensitized individuals [2]. The T3 component of Armour Thyroid is roughly four times more potent per microgram than T4, and its short half-life of approximately 19 hours means daily fluctuations are real.

Adrenal reserve is a second consideration. Low cortisol states, even subclinical ones, can be unmasked when thyroid hormone increases cellular metabolic demand faster than the adrenal axis can respond. Practitioners who follow the work of Drs. Broda Barnes and later John Lowe have historically recommended a cortisol assessment before escalating NDT above 1 grain, though this recommendation remains expert opinion rather than RCT-derived guidance.

The 15 mg / 30 mg Starting-Dose Rationale

Armour Thyroid tablets are commercially available in 15 mg, 30 mg, 60 mg, 90 mg, and 120 mg strengths [3]. The 15 mg tablet contains approximately 9.5 mcg T4 and 2.25 mcg T3. At that dose, serum T3 elevation above baseline is modest and TSH suppression is minimal in most euthyroid-range patients, which makes safety monitoring less urgent in the first weeks.

The 30 mg starting dose, delivering roughly 19 mcg T4 and 4.5 mcg T3, remains below the threshold that would be expected to suppress TSH in most adults with mild-to-moderate primary hypothyroidism. This is the most commonly used microdose entry point in clinical practice.

The Hoang Trial: What the Data Actually Say

The most cited head-to-head comparison of NDT and levothyroxine is Hoang et al., published in the Journal of Clinical Endocrinology and Metabolism in 2013 [4]. The trial enrolled 70 adults with primary hypothyroidism who were already stable on levothyroxine. Participants were randomized to continue their current levothyroxine dose or switch to a weight-based NDT equivalent (approximately 1 mcg levothyroxine per 1 mg NDT) for 16 weeks, then crossed over for another 16 weeks.

Primary Outcomes

TSH values were statistically similar between the two treatment periods. Mean TSH was 2.29 mIU/L on levothyroxine versus 1.85 mIU/L on NDT (P<0.001 for the difference, which narrowly crossed significance but remained within acceptable clinical range for both arms). Free T4 was lower on NDT, and free T3 was higher, reflecting the pharmacokinetic difference between the two formulations.

Body weight fell by a mean of 0.4 kg more on NDT than on levothyroxine, a difference that did not reach significance but drew attention in the patient-reported outcomes [4].

Patient Preference Signal

49% of participants preferred NDT over their baseline levothyroxine regimen, while only 19% preferred levothyroxine. 33% expressed no preference. The authors noted that the preference for NDT was not explained by TSH differences alone, suggesting subjective wellbeing variables, possibly free T3 levels, were influencing the response.

The Hoang team stated: "NDT caused modest weight loss and was preferred by most patients over levothyroxine; therefore, NDT is a viable option for hypothyroid patients who continue to have symptoms while taking levothyroxine." [4]

Limitations Relevant to Microdosing

The Hoang trial did not test sub-replacement doses. All participants were already at steady-state replacement. The study therefore cannot be used to validate any specific microdosing titration schedule. It does, however, confirm that NDT at replacement doses achieves comparable TSH control to levothyroxine, which is the biochemical target that microdosing titration protocols work toward.

Pharmacokinetics That Drive Microdosing Logic

Understanding why NDT is dosed differently from levothyroxine requires a brief look at the kinetics of each hormone in the tablet.

T3 Absorption and Peak

T3 from desiccated thyroid is absorbed rapidly in the jejunum. Peak serum T3 occurs 2-4 hours post-dose, then declines over the next 18-24 hours [2]. This creates a daily oscillation that does not occur with levothyroxine, which relies on peripheral conversion to T3. Some patients find this peak-and-trough pattern symptomatic; others find the T3 peak correlates with improved afternoon energy.

Splitting the daily dose, for example 15 mg in the morning and 15 mg at noon rather than 30 mg as a single dose, attenuates the T3 peak while maintaining the same daily T3 exposure. This is a common adjustment at microdose levels.

T4 Accumulation Over Weeks

T4 in NDT has a half-life of 6-7 days in euthyroid adults [5]. It takes approximately 5 half-lives, or 30-35 days, to reach steady-state serum T4. This means that a 30 mg daily dose initiated today will not show its full biochemical effect on TSH until approximately 5 weeks later. Checking TSH at 2 weeks after starting NDT is premature; the test will underestimate the eventual suppressive effect.

A 4-to-6-week titration interval, the standard recommendation from the American Thyroid Association's 2014 hypothyroidism guidelines [6], exists precisely because of this T4 accumulation window.

A Practical Microdosing Titration Framework

The following framework synthesizes published NDT pharmacokinetics, the Hoang dosing equivalency data, and the ATA 2014 guideline titration principles. No single published RCT validates every step. This is a clinical synthesis, not a protocol derived from a single trial.

Phase 1: Initiation (Weeks 1-4)

Start at 15-30 mg daily, taken on an empty stomach 30-60 minutes before food, coffee, or other medications. Calcium, iron, and proton-pump inhibitors all reduce NDT absorption and should be separated by at least 4 hours [7].

Obtain baseline TSH, free T4, free T3, and a morning cortisol before the first dose. A morning cortisol below 10 mcg/dL warrants evaluation for adrenal insufficiency before proceeding.

Do not recheck thyroid labs until week 4 at the earliest, and week 6 is preferable given T4 kinetics.

Phase 2: First Titration (Weeks 4-8)

At the week 4-6 lab check, compare TSH to the target range of 0.5-2.5 mIU/L. If TSH remains above 4.0 mIU/L and the patient reports tolerable or absent symptoms, increase by one tablet size (15-30 mg increment).

If TSH is 2.5-4.0 mIU/L and the patient feels well, a conservative practitioner may hold the current dose for another 4-6 weeks before deciding to escalate. Free T3 in the lower third of the laboratory reference range at this TSH level often motivates an increase.

Phase 3: Stabilization (Weeks 8-16)

Most patients with mild-to-moderate primary hypothyroidism reach a stable dose between 60 mg (1 grain) and 90 mg (1.5 grains) within 8-16 weeks of microdose initiation. Patients with total thyroidectomy typically require 90-120 mg or more [8].

Once TSH is stable within target range on two consecutive checks 6 weeks apart, monitoring can shift to every 6 months for the first year and annually thereafter, consistent with ATA guidance [6].

Stopping Rules and Dose Reduction Triggers

Reduce or hold the dose if any of the following appear: resting heart rate above 100 bpm on two consecutive readings, palpitations associated with the dose-peak window (2-4 hours post-dose), or TSH below 0.3 mIU/L on any check in a patient without a history of thyroid cancer.

A TSH below 0.1 mIU/L on NDT in a non-cancer patient warrants dose reduction regardless of symptoms. Chronic TSH suppression is associated with atrial fibrillation risk (hazard ratio 1.31 in a 2012 Danish cohort, N=586,460) [9] and reduced bone mineral density in postmenopausal women [10].

NDT vs. Levothyroxine: Where the Evidence Stands in 2025

The 2014 American Thyroid Association guidelines state that levothyroxine monotherapy "remains the standard of care" for hypothyroidism [6]. The 2019 European Thyroid Association guidelines similarly recommend levothyroxine as first-line, while acknowledging that "a trial of combined T4 and T3 therapy" may be appropriate for patients with persistent symptoms on adequate levothyroxine [11].

Neither guideline formally endorses NDT. Both acknowledge the patient-preference data from Hoang and similar observational series.

Where NDT May Offer a Clinical Advantage

Patients with persistently low free T3 despite normal or elevated free T4 on levothyroxine, a pattern sometimes called "poor T4-to-T3 converter," may see symptomatic improvement on NDT. A 2019 meta-analysis of combination T4/T3 therapy (not NDT specifically, but applicable by analogy) found a statistically significant improvement in psychological wellbeing scores when T3 was added to T4 (standardized mean difference 0.24, 95% CI 0.05-0.43, P<0.02) [12].

The DIO2 Thr92Ala polymorphism, present in approximately 12-16% of the population, reduces intracellular T3 production from T4 and may partially explain why some patients feel better on NDT [13]. Genetic testing for this polymorphism is not yet standard of care, but practitioners at specialized thyroid clinics increasingly use it to guide NDT trials.

Where Levothyroxine Remains Superior

Dose precision favors levothyroxine. The fixed 4:1 T4:T3 ratio in NDT cannot be adjusted independently. If a patient needs more T4 and less T3, for example in the setting of cardiac arrhythmia, that granularity is not achievable with NDT alone.

Levothyroxine is also FDA-approved as a narrow therapeutic index drug, meaning manufacturers must demonstrate bioequivalence within tight limits [3]. NDT is a biologic-derived product with inherent batch-to-batch T3 variability reported at up to 10-15% in older formulations [14], though Armour Thyroid underwent a manufacturing reformulation in 2009 intended to improve consistency.

Monitoring Parameters During NDT Microdose Titration

Consistent monitoring protects both the patient and the prescriber.

Lab Panel Timing

• Baseline: TSH, free T4, free T3, morning cortisol (8 AM draw), complete metabolic panel
• Week 5-6: TSH, free T4, free T3 (drawn in the morning before the day's dose)
• Each subsequent titration step: repeat at 5-6 weeks post-change
• Stable maintenance: every 6 months for year 1, then annually

Drawing labs before the morning dose matters. Post-dose T3 peaks can raise free T3 above the reference range transiently, which may create misleading results if blood is drawn 2-4 hours after ingestion.

Symptom Tracking

A structured symptom log, scored at baseline and at each titration visit, provides objective data beyond lab values. The Thyroid Symptom Questionnaire (ThyPRO-39), validated in a 2013 Danish study [15], covers hypothyroid and hyperthyroid symptom domains and can detect subclinical over- or under-treatment that TSH alone may miss.

Persistent fatigue, cold intolerance, constipation, or cognitive slowing at a TSH within range suggests either inadequate T3 delivery or a comorbidity such as iron-deficiency anemia, celiac disease, or sleep apnea, all of which are common in hypothyroid populations [6].

Special Populations and Dose Adjustments

Pregnancy

NDT is not recommended during pregnancy. The T3-to-T4 ratio in NDT does not match the gestational T4 demands of the fetus, which relies heavily on maternal T4 for early brain development. The Endocrine Society's 2012 clinical practice guideline on thyroid disease in pregnancy states that levothyroxine is the treatment of choice and that T3-containing preparations should be avoided [16]. Patients on NDT who become pregnant should transition to levothyroxine immediately.

Elderly Patients (Age 65+)

TSH targets shift upward with age. A TSH of 4-6 mIU/L may be appropriate in a 75-year-old without symptoms, as population norms for TSH rise with age [6]. The T3 pulse from NDT carries greater cardiac risk in older patients, particularly those with undiagnosed coronary artery disease. Starting at 15 mg daily and titrating no faster than every 8 weeks is a reasonable adjustment for patients over 65.

Post-Thyroidectomy Patients

Total thyroidectomy eliminates all endogenous thyroid hormone production. These patients require full replacement, and the dose range is correspondingly higher. Microdosing is only relevant in the very early post-operative period. A 2021 study of post-thyroidectomy patients on NDT (N=94) found that mean stable doses clustered around 90-105 mg daily [8], consistent with earlier weight-based estimates.

What "Original Gain" Looks Like in Real Practice

Published cohort data on pure NDT microdosing initiation is sparse. The existing literature covers stable-dose comparisons, not gradual titration from sub-replacement levels. The clinical frameworks used today are, to a meaningful degree, accumulated practitioner experience rather than trial-validated protocols. That gap is not an argument against the approach. It is an honest description of the evidence base.

The ATA's 2019 research priorities document specifically listed "comparative effectiveness trials of NDT vs. Combination T4/T3 vs. Levothyroxine, including patient-reported outcomes" as a priority area [17], signaling that the field recognizes the evidence deficit. Until those trials are published, microdosing NDT remains a rational clinical practice extrapolated from solid pharmacokinetic data, one well-conducted crossover trial, and guideline-supported titration principles.

Patients considering NDT should understand that "microdosing" describes a starting-dose strategy, not a therapeutic endpoint. The goal is full replacement at the lowest dose that normalizes TSH and free T3 while resolving symptoms. Starting small reduces adverse event risk during the adaptation period. It does not imply that a small dose is the final target.

The ATA guidelines note: "For patients on T4 who continue to have symptoms despite normal serum TSH, clinicians should consider evaluation for other causes of symptoms. A trial of T4/T3 combination therapy may be appropriate in select patients." [6]